In addition, C20/C22 affected the intracellular expression and cell surface distributions of DR4 and DR5, as well as increased the sensitivity of HepG2 to TRAIL-induced apoptosis C20/C22, thus showing potential as an anticancer adjuvant to resume the susceptibility of TRAIL-resistant cancer cells to TRAIL-based anticancer drugs. This evidence concerns the gene TNFSF10 and cancer.